Is the paradigm shifting?
暂无分享,去创建一个
[1] P. Ross,et al. Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study , 2000, Osteoporosis International.
[2] R. Lindsay,et al. Resistance to Bone Resorbing Effects of PTH in Black Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] H. Kopera,et al. Briefe an die Redaktion , 1989, Klinische Wochenschrift.
[4] B. L. Riggs,et al. Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] W. O'Fallon,et al. Primary Hyperparathyroidism and the Risk of Fracture: A Population‐Based Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] L. Joseph Melton,et al. Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] J. Aloia,et al. Biochemical and hormonal variables in black and white women matched for age and weight. , 1998, The Journal of laboratory and clinical medicine.
[8] M. Holick,et al. Nutrition and Bone Health , 2004, Nutrition and Health.
[9] M. McClung. Therapy for fracture prevention. , 1999, JAMA.
[10] J Pearson,et al. Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] R. Eastell,et al. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] G. Blake,et al. Quantitative studies of bone in postmenopausal women using (18)F-fluoride and (99m)Tc-methylene diphosphonate. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] O. Johnell,et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.
[14] M S Calvo,et al. Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] A. Vesterby,et al. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. , 1996, Bone.
[16] R. Epstein,et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. , 1991, Annals of internal medicine.
[17] A. Parfitt. High Bone Turnover Is Intrinsically Harmful: Two Paths to a Similar Conclusion: The Parfitt View , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] Claus Christiansen,et al. Consensus development conference: Prophylaxis and treatment of osteoporosis , 2005, Osteoporosis International.
[19] D. Black,et al. Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] C. Christiansen,et al. Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.
[21] H. Oxlund,et al. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. , 1996, Bone.
[22] C. Slemenda,et al. Age and bone mass as predictors of fracture in a prospective study. , 1988, The Journal of clinical investigation.
[23] M. Hochberg,et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.
[24] D. Burr,et al. Dynamic bone remodeling in later Pleistocene fossil hominids. , 1996, American journal of physical anthropology.
[25] C. Weaver,et al. Changes in calcium kinetics in adolescent girls induced by high calcium intake. , 2000, The Journal of clinical endocrinology and metabolism.
[26] Fran Harris,et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.
[27] I. Chiodini,et al. Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] C. Erem,et al. RELATIONSHIP OF BONE TURNOVER PARAMETERS, ENDOGENOUS HORMONES AND VIT D DEFICIENCY TO HIP FRACTURE IN ELDERLY POSTMENOPAUSAL WOMEN , 2002, International journal of clinical practice.
[29] S. New. Nutrition Society Medal Lecture: The role of the skeleton in acid—base homeostasis , 2002, Proceedings of the Nutrition Society.
[30] C. Cooper,et al. Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] T. Kuhn,et al. The Structure of Scientific Revolutions. , 1964 .
[32] D. Meier,et al. Calcium, vitamin D, and parathyroid hormone status in young white and black women: association with racial differences in bone mass. , 1991, The Journal of clinical endocrinology and metabolism.
[33] L. Melton,et al. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. , 1996, Bone.
[34] M. Burritt,et al. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. , 1996, The Journal of clinical endocrinology and metabolism.
[35] C Marcelli,et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[36] O. Johnell,et al. Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability , 2002, Osteoporosis International.
[37] P. Meunier,et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. , 2000, Bone.
[38] D. Nelson,et al. Calcium in evolutionary perspective. , 1991, The American journal of clinical nutrition.
[39] P. Garnero. Markers of Bone Turnover for the Prediction of Fracture Risk , 2000, Osteoporosis International.
[40] R. Heaney,et al. Bisphosphonate Effects and the Bone Remodeling Transient , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[41] P. Delmas,et al. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] Claus Christiansen,et al. Diagnosis of Osteoporosis , 1992, Southern medical journal.
[43] W. O'Fallon,et al. Relationship of Bone Turnover to Bone Density and Fractures , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.